比瓦利鲁丁与氨酸单疗法在患有ST段升高心肌梗塞的患者中进行初级皮肤冠状动脉干预:随机对照试验的研究水平元分析
1Department of Cardiology, Tang Du Hospital, Air Force Medical University, Shaanxi, China.
Cardiovascular drugs and therapy
|July 30, 2024
概括
在接受初级穿皮冠状动脉干预 (PCI) 的ST段升高心肌梗塞 (STEMI) 患者中,比瓦利鲁丁加PCI后输液显著减少了净不良临床事件 (NACE),主要不良心血管事件 (MACE) 和静脉栓塞 (IST). 这种方法比单独治疗肝素更安全,更有效.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- ST段升高心肌梗塞 (STEMI) 是一种危急的疾病,需要及时的再输血治疗.
- 初级穿皮冠状动脉干预 (PCI) 是STEMI的首选治疗方法.
- 在初级PCI期间和之后的抗凝血策略对于患者的治疗结果至关重要.
研究的目的:
- 在接受初级PCI的STEMI患者中,将比瓦利鲁丁与PCI后输液的安全性和疗效与肝素单一治疗进行比较.
- 评估这些抗凝策略对关键临床结果的影响.
主要方法:
- 进行了随机对照试验 (RCT) 的系统审查和元分析.
- 搜索的数据库包括PubMed,EMBASE,科克莱恩图书馆和科学网.
- 评估的结果包括净不良临床事件 (NACE),主要不良心血管事件 (MACE),静脉栓塞 (IST) 和出血事件 (BARC类型2,3,5).
主要成果:
- 分析包括四个RCT,共发生10695个事件.
- 与肝素相比,比瓦利鲁丁加PCI后输液显著降低了NACEs (RR 0.84,P=0.009),MACEs (RR 0.82,P=0.04) 和ISTs (RR 0.66,P<0.0001).与肝素相比,比瓦利鲁丁加PCI后输液显著降低了NACEs (RR 0.84,P=0.009),MACEs (RR 0.82,P=0.04) 和ISTs (RR 0.66,P<0.0001).
- 在所有死因,心脏病死亡,中风,心肌梗塞,TVR或BARC出血之间没有发现显著差异.
结论:
- 对接受初级PCI的STEMI患者来说,用PCI后输液输入的比瓦利鲁丁是一种比单一治疗氨酸更安全,更有效的策略.
- 这种方案显著降低了NACE,MACE和IST的风险.
- 它不会增加心脏病发作或TVR的风险,并且可能在减少中风,死亡和出血事件方面提供潜在的好处.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481


